But the agency said later it was re-evaluating the decision that the shortage is over amid litigation, putting compounding of ...

The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versi ...

When starting prescription weight loss medications, getting approval from a doctor and insurance is one of the hardest parts.

The FDA became aware of the problem after a patient submitted a complaint to the regulator that a vial of semaglutide from ...

Results from a retrospective cohort study show lower all-cause mortality and fewer hospitalizations and intestinal ...

There’s been lots of attention on type 2 diabetes drugs recently, especially since they might also be able to support weight ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

With a positive readout for metabolic dysfunction-associated steatohepatitis (MASH) now in the bag, Novo Nordisk is gearing ...

Total semaglutide sales rose to a whopping $6.9 billion in the second quarter, but it's losing market share to a ...